FDA
-
-
-
-
-
-
-
60 Degrees Pharmaceuticals enrolls first patient in tafenoquine babesiosis trial
-
-
-
-
-
-
-
60 Degrees Pharmaceuticals files FDA notification for dietary supplement
-
-
-
-
-
-
-
60 Degrees Pharmaceuticals exercises license option for castanospermine
-
-
-
-
-
-
-
60 Degrees Pharmaceuticals Announces Detection of Babesia Infection in 24 Percent of Patients Presenting with Chronic Fatigue in Peer-Reviewed, Sponsored Study at NC State
-
-
-
-
-
-
-
60 Degrees Pharmaceuticals Announces Third Quarter 2025 Results
-
-
-
-
-
-
-
Enlivex Therapeutics and 60 Degrees Pharmaceuticals Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV
-
-
-
-
-
-
-
60 Degrees Pharmaceuticals closes $5 million public offering
-
325,967 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

